PMPRB bias against patients exposed / breach of duty of neutrality. Commissioning Donald J. Savoie to research and write a memorandum the Duty of Neutrality in the context of the PMPRB’s advocacy plan
CORD Letter to Justin Trudeau, Prime Minister of Canada & Patty Hajdu, Minister of Health. Subject: PMPRB Campaign to Discredit Patients and Others Who Do Not Agree with Them
Worst Fears Confirmed! PMPRB Engages in Advocacy Campaign Against Patients
Time to Jump Start Rare Disease Drug Strategy: Open Letter to Prime Minister and Federal Health Minister
Exciting news! CADTH Canadian Expert Drug Committee has recommended reimbursement of Reblozyl/Luspatercept for chronically transfused Beta-Thalassemia patients.
Canadian Organization for Rare Disorders Responds to CADTH Recommendation for SMA Gene Therapy. Gaping Hole for SMA Babies: Why Canada needs National Rare Drug Strategy NOW
Feedback from the Canadian Organization for Rare Disorders for the Public Consultation on Canada’s National Strategy for High-Cost Drugs for Rare Diseases March 2021
CORD Rare Heroes Foundation, Thanks to Estate of Peter Ness and 1st corporate contributor Illumina.
CORD submits House Health Committee HESA hearings on disastrous PMPRB drug pricing rules; supposed to lower prices but instead creates barrier to new medicines for rare diseases #Canada4Rare and other life-saving medicines.
FOR IMMEDIATE RELEASE: October 23, 2020 New PMPRB guidelines can’t fix flaws in regulations that will stall new treatments for Canadian patients
Minister Hajdu, PMPRB: Your drug pricing approach is DEAD Wrong for Patients!
Access to Specialty Drugs Under Pharmacare Survey. This survey is being conducted to learn from Canadians their experiences accessing specialty drugs. In addition, we are asking opinions about how specialty drugs should be available in a National Pharmacare program.